Nile Therapeutics Inc.

In a disease with limited therapies for patient subgroups and a landscape littered with clinical setbacks, Capricor Therapeutics Inc. ’s interim Phase II data indicate that its intravenous cell thera

With the US government reopened, the traditional path to an initial public offering is as well and biopharmaceutical companies are racing down that road as fast as they can in case the temporary end t

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Here's your news in brief: A Duchenne muscular dystrophy (DMD) candidate may finally have some good fortune to bring in terms of efficacy, as Capricor Therapeutics Inc. 's CAP-1002has landed a regene